SCIENTIFIC EVIDENCE

A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in mice.

Frontiers in immunology

Ma Q, Hu X, Liu F, Cao Z, Han L, Zhou K, Bai Y, Zhang Y, Nan Y, Lv Q, Rao J, Wu T, Yang X, He H, Ju D, Xu H.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2022

Bioprocessing

Immunology

No items found.

Key Finding

Moreover, transcriptome analysis revealed the downregulation of signaling pathways associated with injury and dysfunction of the renal parenchymal cell indicating the possible protective mechanisms of anti-ANGPTL3/IL22 in DN. Collectively, anti-ANGPTL3/IL22 bifunctional fusion protein can be a promising novel therapeutic strategy for DN by reducing podocyte injury, ameliorating inflammatory response, and enhancing renal tissue recovery.

Countstar Connection

Using a Countstar instrument, the study assessed cell number and viability in the study's cell samples during culture monitoring in the 2022 Frontiers in immunology study.

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online